Recent Updates
Recently added Catalysts
ACHC Positive Sentiment

Acadia To Present at the 44th Annual J.P. Morgan Healthcare Conference

Wednesday, January 7, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Acadia Healthcare will present at the 44th Annual J.P. Morgan Healthcare Conference from January 12-15 in San Francisco. The presentation will be available on their website starting January 13 at 7:15 p.m. Central time. This participation underscores Acadia's engagement with investors and the healthcare community.
Price reaction · baseline $14.615 (2026-01-07T15:44:00.000Z) · hit during market hours · clean, no other ACHC news in the window
day 0 close
-6.2%
day 1
-8%
day 3 · peak
-9.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • Acadia Healthcare is participating in a prestigious conference.
  • The presentation will be accessible online for investors.
  • The event highlights Acadia's commitment to transparency.

Full Press Release Details

Acadia Healthcare will participate in the 44 th Annual J.P. Morgan Healthcare Conference on January 12-15. The conference is being held in San Francisco, California, and our presentation will be available on our website beginning at 7:15 p.m. Central time Tuesday, January 13. The webcast can be viewed on the Investors page .
Read More

Frequently Asked Questions

When is Acadia's presentation at the conference?

Acadia's presentation will be available on January 13 at 7:15 p.m. Central time.

Where is the J.P. Morgan Healthcare Conference held?

The conference is being held in San Francisco, California.

How can I view Acadia's presentation?

The presentation can be viewed on Acadia's Investors page on their website.

What is the date range of the conference?

The conference takes place from January 12 to January 15.

ShareAdd on Google
Tags: ACHC Viatris Investor Conferences Healthcare Acadia Healthcare J.P. Morgan healthcare conference investors presentation
Last updated: Jan 7, 2026

Biotech snapshot

Cash runway
$171M liquidity · $0M/mo burn
Low dilution risk